Physicochemical Properties
| Molecular Formula | C15H15BRF3N7 |
| Molecular Weight | 430.23 |
| Exact Mass | 429.052 |
| CAS # | 2109805-78-7 |
| PubChem CID | 132585209 |
| Appearance | Typically exists as solid at room temperature |
| Density | 1.9±0.1 g/cm3 |
| Index of Refraction | 1.750 |
| LogP | 1.78 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 2 |
| Heavy Atom Count | 26 |
| Complexity | 510 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | BrC1=C(N)N2C(=C(C=N2)C2C=NN(C(F)(F)F)C=2)N=C1[C@H]1CNCCC1 |
| InChi Key | MJZFYQKXEVDVRY-MRVPVSSYSA-N |
| InChi Code | InChI=1S/C15H15BrF3N7/c16-11-12(8-2-1-3-21-4-8)24-14-10(6-23-26(14)13(11)20)9-5-22-25(7-9)15(17,18)19/h5-8,21H,1-4,20H2/t8-/m1/s1 |
| Chemical Name | 6-bromo-5-[(3R)-piperidin-3-yl]-3-[1-(trifluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyrimidin-7-amine |
| Synonyms | MU380; MU 380; MU-380 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Effectively inhibiting CHK1 sleep lymphoma cells and sensitizing them to gemcitabine is MU380 (100 nM, 24 h) [1]. MU380 (400 nM, 24 h) can dramatically alter cell cycle patterns and cause primary chronic lymphocytes that are dividing or not to undergo apoptosis [1]. |
| ln Vivo | Mouse tumor growth can be effectively inhibited by MU380 (20 mg/kg, once every three days from day 14 to day 28) using a 20% Kolliphor aqueous solution [1]. |
| Cell Assay |
Apoptosis Analysis[1] Cell Types: MEC-1 and MEC-2 Cell Tested Concentrations: 400 nM Incubation Duration: 24 h Experimental Results: It shows the accumulation of S phase and the reduction of G2/M phase, the DNA synthesis rate is greatly diminished, and cell apoptosis (PARP protein cleavage) is Dramatically induced. Western Blot Analysis[1] Cell Types: Chronic Lymphocytic Leukemia Cells Tested Concentrations: 100 nM or 200 nM Incubation Duration: 24 hrs (hours) Experimental Results: Effectively blocks CHK1 activation while enhancing ATR kinase signaling to CHK1 (pS317 and pS345) and leading to CHK1 levels diminished total CDC25A and CDC25C, pY15 CDK1, cyclin B1, and cyclin E1. |
| Animal Protocol |
Animal/Disease Models: NOD-scid IL2Rγnull mice [1] Doses: 20 mg/kg Route of Administration: 20% Kolliphor aqueous solution, once every three days from day 14 to day 28. Experimental Results: Dramatically inhibited tumor growth, and The tumor volume is gradually diminished, with an average reduction of approximately 61%. |
| References |
[1]. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Haematologica. 2019 Dec;104(12):2443-2455. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3243 mL | 11.6217 mL | 23.2434 mL | |
| 5 mM | 0.4649 mL | 2.3243 mL | 4.6487 mL | |
| 10 mM | 0.2324 mL | 1.1622 mL | 2.3243 mL |